Cargando…

Baseline Morbidity in 2,990 Adult African Volunteers Recruited to Characterize Laboratory Reference Intervals for Future HIV Vaccine Clinical Trials

BACKGROUND: An understanding of the health of potential volunteers in Africa is essential for the safe and efficient conduct of clinical trials, particularly for trials of preventive technologies such as vaccines that enroll healthy individuals. Clinical safety laboratory values used for screening,...

Descripción completa

Detalles Bibliográficos
Autores principales: Stevens, Wendy, Kamali, Anatoli, Karita, Etienne, Anzala, Omu, Sanders, Eduard J., Jaoko, Walter, Kaleebu, Pontiano, Mulenga, Joseph, Dally, Len, Fast, Pat, Gilmour, Jill, Farah, Bashir, Birungi, Josephine, Hughes, Peter, Manigart, Olivier, Stevens, Gwynn, Yates, Sarah, Thomson, Helen, von Lieven, Andrea, Krebs, Marietta, Price, Matt A., Stoll-Johnson, Lisa, Ketter, Nzeera
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2312327/
https://www.ncbi.nlm.nih.gov/pubmed/18446196
http://dx.doi.org/10.1371/journal.pone.0002043
_version_ 1782152572154413056
author Stevens, Wendy
Kamali, Anatoli
Karita, Etienne
Anzala, Omu
Sanders, Eduard J.
Jaoko, Walter
Kaleebu, Pontiano
Mulenga, Joseph
Dally, Len
Fast, Pat
Gilmour, Jill
Farah, Bashir
Birungi, Josephine
Hughes, Peter
Manigart, Olivier
Stevens, Gwynn
Yates, Sarah
Thomson, Helen
von Lieven, Andrea
Krebs, Marietta
Price, Matt A.
Stoll-Johnson, Lisa
Ketter, Nzeera
author_facet Stevens, Wendy
Kamali, Anatoli
Karita, Etienne
Anzala, Omu
Sanders, Eduard J.
Jaoko, Walter
Kaleebu, Pontiano
Mulenga, Joseph
Dally, Len
Fast, Pat
Gilmour, Jill
Farah, Bashir
Birungi, Josephine
Hughes, Peter
Manigart, Olivier
Stevens, Gwynn
Yates, Sarah
Thomson, Helen
von Lieven, Andrea
Krebs, Marietta
Price, Matt A.
Stoll-Johnson, Lisa
Ketter, Nzeera
author_sort Stevens, Wendy
collection PubMed
description BACKGROUND: An understanding of the health of potential volunteers in Africa is essential for the safe and efficient conduct of clinical trials, particularly for trials of preventive technologies such as vaccines that enroll healthy individuals. Clinical safety laboratory values used for screening, enrolment and follow-up of African clinical trial volunteers have largely been based on values derived from industrialized countries in Europe and North America. This report describes baseline morbidity during recruitment for a multi-center, African laboratory reference intervals study. METHODS: Asymptomatic persons, aged 18–60 years, were invited to participate in a cross-sectional study at seven sites (Kigali, Rwanda; Masaka and Entebbe, Uganda; Kangemi, Kenyatta National Hospital and Kilifi, Kenya; and Lusaka, Zambia). Gender equivalency was by design. Individuals who were acutely ill, pregnant, menstruating, or had significant clinical findings were not enrolled. Each volunteer provided blood for hematology, immunology, and biochemistry parameters and urine for urinalysis. Enrolled volunteers were excluded if found to be positive for HIV, syphilis or Hepatitis B and C. Laboratory assays were conducted under Good Clinical Laboratory Practices (GCLP). RESULTS AND CONCLUSIONS: Of the 2990 volunteers who were screened, 2387 (80%) were enrolled, and 2107 (71%) were included in the analysis (52% men, 48% women). Major reasons for screening out volunteers included abnormal findings on physical examination (228/603, 38%), significant medical history (76, 13%) and inability to complete the informed consent process (73, 13%). Once enrolled, principle reasons for exclusion from analysis included detection of Hepatitis B surface antigen (106/280, 38%) and antibodies against Hepatitis C (95, 34%). This is the first large scale, multi-site study conducted to the standards of GCLP to describe African laboratory reference intervals applicable to potential volunteers in clinical trials. Approximately one-third of all potential volunteers screened were not eligible for analysis; the majority were excluded for medical reasons.
format Text
id pubmed-2312327
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-23123272008-04-30 Baseline Morbidity in 2,990 Adult African Volunteers Recruited to Characterize Laboratory Reference Intervals for Future HIV Vaccine Clinical Trials Stevens, Wendy Kamali, Anatoli Karita, Etienne Anzala, Omu Sanders, Eduard J. Jaoko, Walter Kaleebu, Pontiano Mulenga, Joseph Dally, Len Fast, Pat Gilmour, Jill Farah, Bashir Birungi, Josephine Hughes, Peter Manigart, Olivier Stevens, Gwynn Yates, Sarah Thomson, Helen von Lieven, Andrea Krebs, Marietta Price, Matt A. Stoll-Johnson, Lisa Ketter, Nzeera PLoS One Research Article BACKGROUND: An understanding of the health of potential volunteers in Africa is essential for the safe and efficient conduct of clinical trials, particularly for trials of preventive technologies such as vaccines that enroll healthy individuals. Clinical safety laboratory values used for screening, enrolment and follow-up of African clinical trial volunteers have largely been based on values derived from industrialized countries in Europe and North America. This report describes baseline morbidity during recruitment for a multi-center, African laboratory reference intervals study. METHODS: Asymptomatic persons, aged 18–60 years, were invited to participate in a cross-sectional study at seven sites (Kigali, Rwanda; Masaka and Entebbe, Uganda; Kangemi, Kenyatta National Hospital and Kilifi, Kenya; and Lusaka, Zambia). Gender equivalency was by design. Individuals who were acutely ill, pregnant, menstruating, or had significant clinical findings were not enrolled. Each volunteer provided blood for hematology, immunology, and biochemistry parameters and urine for urinalysis. Enrolled volunteers were excluded if found to be positive for HIV, syphilis or Hepatitis B and C. Laboratory assays were conducted under Good Clinical Laboratory Practices (GCLP). RESULTS AND CONCLUSIONS: Of the 2990 volunteers who were screened, 2387 (80%) were enrolled, and 2107 (71%) were included in the analysis (52% men, 48% women). Major reasons for screening out volunteers included abnormal findings on physical examination (228/603, 38%), significant medical history (76, 13%) and inability to complete the informed consent process (73, 13%). Once enrolled, principle reasons for exclusion from analysis included detection of Hepatitis B surface antigen (106/280, 38%) and antibodies against Hepatitis C (95, 34%). This is the first large scale, multi-site study conducted to the standards of GCLP to describe African laboratory reference intervals applicable to potential volunteers in clinical trials. Approximately one-third of all potential volunteers screened were not eligible for analysis; the majority were excluded for medical reasons. Public Library of Science 2008-04-30 /pmc/articles/PMC2312327/ /pubmed/18446196 http://dx.doi.org/10.1371/journal.pone.0002043 Text en Stevens et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Stevens, Wendy
Kamali, Anatoli
Karita, Etienne
Anzala, Omu
Sanders, Eduard J.
Jaoko, Walter
Kaleebu, Pontiano
Mulenga, Joseph
Dally, Len
Fast, Pat
Gilmour, Jill
Farah, Bashir
Birungi, Josephine
Hughes, Peter
Manigart, Olivier
Stevens, Gwynn
Yates, Sarah
Thomson, Helen
von Lieven, Andrea
Krebs, Marietta
Price, Matt A.
Stoll-Johnson, Lisa
Ketter, Nzeera
Baseline Morbidity in 2,990 Adult African Volunteers Recruited to Characterize Laboratory Reference Intervals for Future HIV Vaccine Clinical Trials
title Baseline Morbidity in 2,990 Adult African Volunteers Recruited to Characterize Laboratory Reference Intervals for Future HIV Vaccine Clinical Trials
title_full Baseline Morbidity in 2,990 Adult African Volunteers Recruited to Characterize Laboratory Reference Intervals for Future HIV Vaccine Clinical Trials
title_fullStr Baseline Morbidity in 2,990 Adult African Volunteers Recruited to Characterize Laboratory Reference Intervals for Future HIV Vaccine Clinical Trials
title_full_unstemmed Baseline Morbidity in 2,990 Adult African Volunteers Recruited to Characterize Laboratory Reference Intervals for Future HIV Vaccine Clinical Trials
title_short Baseline Morbidity in 2,990 Adult African Volunteers Recruited to Characterize Laboratory Reference Intervals for Future HIV Vaccine Clinical Trials
title_sort baseline morbidity in 2,990 adult african volunteers recruited to characterize laboratory reference intervals for future hiv vaccine clinical trials
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2312327/
https://www.ncbi.nlm.nih.gov/pubmed/18446196
http://dx.doi.org/10.1371/journal.pone.0002043
work_keys_str_mv AT stevenswendy baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials
AT kamalianatoli baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials
AT karitaetienne baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials
AT anzalaomu baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials
AT sanderseduardj baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials
AT jaokowalter baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials
AT kaleebupontiano baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials
AT mulengajoseph baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials
AT dallylen baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials
AT fastpat baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials
AT gilmourjill baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials
AT farahbashir baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials
AT birungijosephine baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials
AT hughespeter baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials
AT manigartolivier baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials
AT stevensgwynn baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials
AT yatessarah baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials
AT thomsonhelen baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials
AT vonlievenandrea baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials
AT krebsmarietta baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials
AT pricematta baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials
AT stolljohnsonlisa baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials
AT ketternzeera baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials